Dasatinib phase I/II study of patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib: Results of the CA180031 study in Japan

被引：0

作者：

Sakamaki, H.

Ishizawa, K.

Taniwaki, M.

Fujisawa, S.

Morishima, Y.

Tobinai, K.

Okada, M.

Ando, K.

Ueda, K.

Ohno, R.

机构：

[1] Metropolitan Komagome Hosp, Tokyo, Japan

[2] Tohoku Univ, Sendai, Miyagi, Japan

[3] Kyoto Prefectural Univ Med, Kyoto, Japan

[4] Yokohama City Univ, Med Ctr, Yokohama, Kanagawa, Japan

[5] Aichi Canc Ctr, Nagoya, Aichi, Japan

[6] Natl Canc Ctr, Tokyo, Japan

[7] Hyogo Med Univ, Kobe, Hyogo, Japan

[8] Tokai Univ, Hiratsuka, Kanagawa, Japan

[9] Bristol Myers Squibb, Tokyo, Japan

[10] Aichi Shukutoku Univ, Nagakute, Aichi, Japan

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

17515

引用

页数：2